| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2023 | 117.39% | Mizuho | → $2 | Initiates Coverage On | → Buy |
| 09/05/2023 | 552.17% | Truist Securities | → $6 | Reiterates | Buy → Buy |
| 08/11/2023 | 334.78% | Chardan Capital | $2 → $4 | Upgrades | Neutral → Buy |
| 03/07/2023 | 117.39% | Ladenburg Thalmann | → $2 | Initiates Coverage On | → Buy |
| 11/11/2022 | 117.39% | Chardan Capital | $2.5 → $2 | Maintains | Neutral |
| 11/11/2022 | 226.09% | RBC Capital | $5 → $3 | Maintains | Sector Perform |
| 08/12/2022 | 171.74% | Chardan Capital | $3 → $2.5 | Maintains | Neutral |
| 07/07/2022 | 334.78% | Truist Securities | $3 → $4 | Upgrades | Hold → Buy |
| 07/23/2021 | 226.09% | Chardan Capital | $5 → $3 | Maintains | Neutral |
| 07/23/2021 | 226.09% | Cantor Fitzgerald | $23 → $3 | Downgrades | Overweight → Neutral |
| 07/23/2021 | 117.39% | SVB Leerink | $5 → $2 | Maintains | Market Perform |
| 05/03/2021 | 443.48% | SVB Leerink | → $5 | Downgrades | Outperform → Market Perform |
| 04/29/2021 | 443.48% | Chardan Capital | $20 → $5 | Downgrades | Buy → Neutral |
| 04/29/2021 | 878.26% | Truist Securities | $30 → $9 | Downgrades | Buy → Hold |
| 04/29/2021 | 552.17% | RBC Capital | → $6 | Downgrades | Outperform → Sector Perform |
| 04/29/2021 | 1095.65% | SVB Leerink | $21 → $11 | Maintains | Outperform |
| 11/12/2020 | — | Raymond James | Upgrades | Underperform → Market Perform | |
| 08/11/2020 | 2182.61% | SVB Leerink | $20 → $21 | Maintains | Outperform |
| 05/13/2020 | 2508.7% | RBC Capital | → $24 | Initiates Coverage On | → Outperform |
| 05/05/2020 | 2182.61% | SunTrust Robinson Humphrey | → $21 | Upgrades | Hold → Buy |
| 05/05/2020 | 2073.91% | SVB Leerink | $17 → $20 | Maintains | Outperform |
| 04/28/2020 | 1747.83% | Goldman Sachs | → $17 | Initiates Coverage On | → Buy |
| 03/16/2020 | 1747.83% | SVB Leerink | → $17 | Initiates Coverage On | → Outperform |
| 02/10/2020 | 2073.91% | Chardan Capital | $10 → $20 | Upgrades | Neutral → Buy |
| 02/10/2020 | 2182.61% | Cantor Fitzgerald | $8 → $21 | Upgrades | Neutral → Overweight |
| 01/13/2020 | 2073.91% | Piper Sandler | $14 → $20 | Reiterates | → Overweight |
| 09/13/2019 | 769.57% | SunTrust Robinson Humphrey | $12 → $8 | Maintains | Hold |
| 06/14/2019 | — | Raymond James | Reinstates | → Market Perform | |
| 11/05/2018 | 334.78% | Cantor Fitzgerald | $12 → $4 | Downgrades | Overweight → Neutral |
| 11/02/2018 | — | SunTrust Robinson Humphrey | Downgrades | Buy → Hold | |
| 11/02/2018 | — | Raymond James | Downgrades | Outperform → Market Perform |
What is the target price for Adverum Biotechnologies (ADVM)?
The latest price target for Adverum Biotechnologies (NASDAQ: ADVM) was reported by Mizuho on November 2, 2023. The analyst firm set a price target for $2.00 expecting ADVM to rise to within 12 months (a possible 117.39% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adverum Biotechnologies (ADVM)?
The latest analyst rating for Adverum Biotechnologies (NASDAQ: ADVM) was provided by Mizuho, and Adverum Biotechnologies initiated their buy rating.
When is the next analyst rating going to be posted or updated for Adverum Biotechnologies (ADVM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adverum Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adverum Biotechnologies was filed on November 2, 2023 so you should expect the next rating to be made available sometime around November 2, 2024.
Is the Analyst Rating Adverum Biotechnologies (ADVM) correct?
While ratings are subjective and will change, the latest Adverum Biotechnologies (ADVM) rating was a initiated with a price target of $0.00 to $2.00. The current price Adverum Biotechnologies (ADVM) is trading at is $0.92, which is within the analyst's predicted range.